245 related articles for article (PubMed ID: 29961279)
1. [Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia].
Xue W; Yang JJ; Zhao J; Ren T; Feng FZ; Wan XR; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):377-383. PubMed ID: 29961279
[No Abstract] [Full Text] [Related]
2. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5.
Li Y; Kong Y; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
Oncologist; 2021 Dec; 26(12):e2209-e2216. PubMed ID: 34396643
[TBL] [Abstract][Full Text] [Related]
3. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
Yang J; Xiang Y; Wan X; Feng F; Ren T
Gynecol Oncol; 2016 Oct; 143(1):68-72. PubMed ID: 27426306
[TBL] [Abstract][Full Text] [Related]
4. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
5. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
6. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
7. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
Deng L; Zhang J; Wu T; Lawrie TA
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
[TBL] [Abstract][Full Text] [Related]
9. Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
Ji M; Jiang S; Zhao J; Wan X; Feng F; Ren T; Yang J; Xiang Y
Br J Cancer; 2022 Aug; 127(3):524-530. PubMed ID: 35459802
[TBL] [Abstract][Full Text] [Related]
10. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis.
Li J; Yue H; Wang X; Chen R; Lu X
Eur J Obstet Gynecol Reprod Biol; 2019 Jul; 238():164-169. PubMed ID: 31136884
[TBL] [Abstract][Full Text] [Related]
12. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
[TBL] [Abstract][Full Text] [Related]
13. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy regimen with floxuridine, dactinomycin, etoposide, and vincristine as primary treatment for gestational trophoblastic neoplasia.
Wang T; Feng FZ; Xiang Y; Wan XR; Ren T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Jun; 36(3):300-4. PubMed ID: 24997824
[TBL] [Abstract][Full Text] [Related]
15. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
Feng F; Xiang Y; Wan X; Geng S; Wang T
Ann Oncol; 2011 Jul; 22(7):1588-1594. PubMed ID: 21239399
[TBL] [Abstract][Full Text] [Related]
16. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
17. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
18. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
19. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
20. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X
Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
